Vorapaxar From Lead Identification to FDA Approval

Lead Generation Methods, Stiratepes, and Case Studies, First Edition. Edited by Jorg Holenz. 

Antiplatelets are the mainstay of treatment for acute coronary syndrome (ACS), a spectrum of ischemic events that include myocardial infarction and unstable angina, with well-established benefit in preventing atherothrombosis. Results of a meta-analysis of 145 clinical studies reported a 25% reduction of atherothrombotic events in high-risk patients treated with antiplatelet therapy [12]. Another meta-analysis of 109 clinical trials has concluded that antiplatelet medications were able to reduce transient ischemic attacks and strokes by 22%, reduce coronary artery disease by 29%, and reduce peripheral artery disease by 23% [13]. Table 19.1 summarizes the major commercially available antiplatelet agents. 

Generic name or code name Brand name Formulation Status 

Cyclooxygenase inhibitor Acetyl salicylic add Aspirin Oral Launched 

ADP(P2Yj2) antagonists Ticlopidine Ticlid Oral Launched 

---